CN1367702A - 肾细胞癌治疗 - Google Patents

肾细胞癌治疗 Download PDF

Info

Publication number
CN1367702A
CN1367702A CN00808740A CN00808740A CN1367702A CN 1367702 A CN1367702 A CN 1367702A CN 00808740 A CN00808740 A CN 00808740A CN 00808740 A CN00808740 A CN 00808740A CN 1367702 A CN1367702 A CN 1367702A
Authority
CN
China
Prior art keywords
patient
pegylated interferon
interferon alpha
alpha
micrograms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00808740A
Other languages
English (en)
Chinese (zh)
Inventor
E·H·罗斯
M·E·赖巴克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1367702A publication Critical patent/CN1367702A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN00808740A 1999-04-08 2000-04-06 肾细胞癌治疗 Pending CN1367702A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08
US09/288,359 1999-04-08

Publications (1)

Publication Number Publication Date
CN1367702A true CN1367702A (zh) 2002-09-04

Family

ID=23106761

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00808740A Pending CN1367702A (zh) 1999-04-08 2000-04-06 肾细胞癌治疗

Country Status (23)

Country Link
EP (2) EP1043025B1 (https=)
JP (2) JP3712914B2 (https=)
CN (1) CN1367702A (https=)
AR (1) AR029160A1 (https=)
AT (2) ATE296638T1 (https=)
AU (2) AU777406B2 (https=)
BR (1) BR0009644A (https=)
CA (1) CA2303752A1 (https=)
CO (1) CO5170412A1 (https=)
CY (1) CY1108919T1 (https=)
DE (2) DE60041291D1 (https=)
DK (2) DK1043025T3 (https=)
ES (2) ES2239953T3 (https=)
HU (1) HU230271B1 (https=)
MX (1) MXPA00003401A (https=)
MY (1) MY155221A (https=)
NO (1) NO328983B1 (https=)
NZ (1) NZ514629A (https=)
PE (1) PE20010026A1 (https=)
PT (2) PT1043025E (https=)
TW (2) TWI310314B (https=)
WO (1) WO2000061174A2 (https=)
ZA (1) ZA200108169B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103463623A (zh) * 2013-09-03 2013-12-25 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2303752A1 (en) * 1999-04-08 2000-10-08 Schering Corporation Renal cell carcinoma treatment
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
ES2891564T3 (es) 2010-04-01 2022-01-28 Oncorena Ab Tratamiento mejorado del carcinoma de células renales
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
WO2024186735A1 (en) * 2023-03-03 2024-09-12 Memorial Sloan-Kettering Cancer Center Methods and compositions for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
WO1999048535A1 (en) * 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
CA2303752A1 (en) * 1999-04-08 2000-10-08 Schering Corporation Renal cell carcinoma treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103463623A (zh) * 2013-09-03 2013-12-25 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法

Also Published As

Publication number Publication date
HK1032533A1 (en) 2001-07-27
JP2001288110A (ja) 2001-10-16
DK1535623T3 (da) 2009-04-27
ZA200108169B (en) 2003-01-06
MY155221A (en) 2015-09-30
CA2303752A1 (en) 2000-10-08
JP2000319196A (ja) 2000-11-21
EP1535623A1 (en) 2005-06-01
NO20014851L (no) 2001-12-07
TWI310314B (en) 2009-06-01
DE60020442D1 (de) 2005-07-07
NZ514629A (en) 2004-02-27
HUP0200781A2 (en) 2002-08-28
DE60020442T2 (de) 2006-05-04
AU2004242454A1 (en) 2005-01-20
CO5170412A1 (es) 2002-06-27
DE60041291D1 (de) 2009-02-12
EP1043025A3 (en) 2000-12-20
TW200526243A (en) 2005-08-16
NO328983B1 (no) 2010-07-05
JP3712914B2 (ja) 2005-11-02
CY1108919T1 (el) 2014-07-02
EP1043025A2 (en) 2000-10-11
WO2000061174A2 (en) 2000-10-19
NO20014851D0 (no) 2001-10-05
HU230271B1 (hu) 2015-11-30
AU2004242454B2 (en) 2007-02-15
AR029160A1 (es) 2003-06-18
BR0009644A (pt) 2002-01-08
JP4721488B2 (ja) 2011-07-13
HK1075417A1 (en) 2005-12-16
AU777406B2 (en) 2004-10-14
DK1043025T3 (da) 2005-07-04
PT1535623E (pt) 2009-03-19
ES2239953T3 (es) 2005-10-16
PE20010026A1 (es) 2001-02-05
HUP0200781A3 (en) 2002-09-30
MXPA00003401A (es) 2002-03-08
ATE419002T1 (de) 2009-01-15
ATE296638T1 (de) 2005-06-15
AU4204400A (en) 2000-11-14
PT1043025E (pt) 2005-09-30
WO2000061174A3 (en) 2001-01-25
EP1043025B1 (en) 2005-06-01
ES2319777T3 (es) 2009-05-12
EP1535623B1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
US7482014B2 (en) Melanoma therapy
CN1367702A (zh) 肾细胞癌治疗
US6605273B2 (en) Renal cell carcinoma treatment
JP2001288110A6 (ja) 腎細胞ガン処置
EP1043026B1 (en) Melanoma therapy
AU2004242456B2 (en) CML therapy
HK1032533B (en) Renal cell carcinoma treatment
HK1075417B (en) Renal cell carcinoma treatment
JP2001288109A (ja) 黒色腫治療
HK1032349B (en) Melanoma therapy
MXPA00003345A (en) Melanoma therapy
JP2001288109A6 (ja) 黒色腫治療

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication